US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CITIUS ONCOLOGY INC

1.24

+0.05504.66%

Volume:145.82K

Turnover:171.04K

Market Cap:109.02M

PE:-3.65

High:1.24

Open:1.20

Low:1.14

Close:1.18

52wk High:6.19

52wk Low:0.5506

Shares:88.28M

Float Shares:12.32M

Volume Ratio:1.53

T/O Rate:1.18%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3380

EPS(LYR):-0.3380

ROE:-54.42%

ROA:-15.87%

PB:2.43

PE(LYR):-3.65

Loading ...

Overview Company News Filings

Citius Oncology Inc. posts Q1 net loss of USD 5.53 million, down 17 percent

Citius Pharma Q1 stock-based compensation expense rises to USD 3.56 million, up 97%

Citius Oncology Signs Exclusive Distribution Agreement With Uniphar for LYMPHIR in Europe

Citius Oncology Expands International Distribution of Lymphir™ to European Union Through Exclusive Agreement With Uniphar

THOMSON REUTERS

Citius Oncology Inc. Files Information Statement Detailing Authorized Corporate Actions

Citius Oncology Inc. Files Draft Information Statement Outlining Authorized Corporate Actions

Citius Oncology Q4 EPS $(0.06), Inline

Citius Oncology posts FY cash balance of USD 3.9 million and accumulated deficit of USD 64.0 million

Citius Oncology Announces Warrant and Share Issuance in $18 Million Offering

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS

Citius Oncology Sells Shares and Warrants in $18 Million Private Placement

Citius Oncology Inc - Proceeds Support Launch of Lymphir for Cutaneous T-Cell Lymphoma

THOMSON REUTERS

Citius Oncology Inc - to Purchase 1,284,404 Shares of Common Stock at $1.09 per Share in Direct Offering

THOMSON REUTERS

Press Release: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

BRIEF-Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries

Citius Oncology Expands Lymphir™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement With Er-Kim

THOMSON REUTERS

Citius Pharmaceuticals Highlights Oncology Pipeline and LYMPHIR Launch in New Corporate Presentation

BRIEF-Citius Oncology Announces U.S. Commercial Launch Of Lymphir For Cutaneous T-Cell Lymphoma

Citius Oncology Shares Rise After Cancer Treatment Launches

Citius Oncology Announces U.S. Commercial Launch of Lymphir™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (Ctcl)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CTOR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTOR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","market":"US","secType":"STK","nameCN":"CITIUS ONCOLOGY INC","latestPrice":1.235,"timestamp":1771004386172,"preClose":1.18,"halted":0,"volume":145819,"delay":0,"changeRate":0.04661016949152556,"floatShares":12321000,"shares":88275200,"eps":-0.337956,"marketStatus":"Trading","change":0.055,"latestTime":"02-13 12:39:54 EST","open":1.2,"high":1.235,"low":1.14,"amount":171040.5687531,"amplitude":0.080508,"askPrice":1.25,"askSize":700,"bidPrice":1.23,"bidSize":398,"shortable":3,"etf":0,"ttmEps":-0.337956,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771016400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.18,"preHourTrading":{"tag":"盘前","latestPrice":1.22,"preClose":1.18,"latestTime":"09:22 EST","volume":9699,"amount":11605.204603799999,"timestamp":1770992568853,"change":0.04,"changeRate":0.033898,"amplitude":0.067797},"postHourTrading":{"tag":"盘后","latestPrice":1.2,"preClose":1.18,"latestTime":"19:29 EST","volume":5011,"amount":6015.1685,"timestamp":1770942590229,"change":0.02,"changeRate":0.016949,"amplitude":0.042373},"volumeRatio":1.52937},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","floatShares":12321000,"roa":"-15.87%","roe":"-54.42%","lyrEps":-0.337956,"volumeRatio":1.52937,"shares":88275200,"dividePrice":0,"high":1.235,"amplitude":0.080508,"preClose":1.18,"low":1.14,"week52Low":0.5506,"pbRate":"2.43","week52High":6.19,"institutionHeld":0,"latestPrice":1.235,"committee":-0.275046,"eps":-0.337956,"divideRate":0,"volume":145819,"delay":0,"ttmEps":-0.337956,"open":1.2,"prevYearClose":1,"prevWeekClose":1.13,"prevMonthClose":1.06,"prevQuarterClose":1,"fiveDayClose":1.13,"twentyDayClose":1.08,"sixtyDayClose":1.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTOR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-23","symbol":"CTOR","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1766466000000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2025-08-12","symbol":"CTOR","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.08}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTOR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTOR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1758603600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTOR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTOR","date":"2026-02-12","current":-3.491579,"percent":0.51752,"low":-14.569058,"twenty":-5.687458,"median":-4.061643,"eighty":-3.39493,"high":-1.770477,"avg":-4.53108,"sd":1.897625,"marketCap":99750980},"quantilePoints":[{"date":"2024-08-23","current":-7.506449,"twenty":-8.175502,"median":-7.996,"eighty":-7.800179,"marketCap":131199450},{"date":"2024-08-30","current":-6.464428,"twenty":-8.028637,"median":-7.567643,"eighty":-6.639734,"marketCap":126208166},{"date":"2024-09-06","current":-6.847911,"twenty":-7.922567,"median":-7.149219,"eighty":-6.405992,"marketCap":133695091},{"date":"2024-09-13","current":-5.989639,"twenty":-7.726747,"median":-6.50095,"eighty":-6.274513,"marketCap":116938640},{"date":"2024-09-20","current":-6.099206,"twenty":-7.555404,"median":-6.464428,"eighty":-5.97503,"marketCap":119077761},{"date":"2024-09-27","current":-5.222673,"twenty":-7.472896,"median":-6.354861,"eighty":-5.953117,"marketCap":101964790},{"date":"2024-10-04","current":-4.309619,"twenty":-7.088957,"median":-6.190511,"eighty":-5.617113,"marketCap":84138777},{"date":"2024-10-11","current":-3.542653,"twenty":-6.749301,"median":-6.099206,"eighty":-5.018149,"marketCap":69164927},{"date":"2024-10-18","current":-3.944397,"twenty":-6.661648,"median":-5.953117,"eighty":-4.16353,"marketCap":77008372},{"date":"2024-10-25","current":-4.399098,"twenty":-6.559386,"median":-5.916595,"eighty":-4.331532,"marketCap":85885727},{"date":"2024-10-31","current":-4.419185,"twenty":-6.486341,"median":-5.66094,"eighty":-4.324228,"marketCap":86277899},{"date":"2024-11-08","current":-4.602892,"twenty":-6.464428,"median":-5.16789,"eighty":-4.287705,"marketCap":89864492},{"date":"2024-11-15","current":-3.904222,"twenty":-6.464428,"median":-4.930496,"eighty":-4.287705,"marketCap":76224028},{"date":"2024-11-22","current":-3.564201,"twenty":-6.420601,"median":-4.784407,"eighty":-3.944397,"marketCap":69585621},{"date":"2024-11-29","current":-3.356755,"twenty":-6.347557,"median":-4.693102,"eighty":-3.842134,"marketCap":65535551},{"date":"2024-12-06","current":-5.916595,"twenty":-6.296426,"median":-4.747885,"eighty":-3.776395,"marketCap":115512559},{"date":"2024-12-13","current":-3.907874,"twenty":-6.201468,"median":-4.620605,"eighty":-3.842134,"marketCap":76295332},{"date":"2024-12-20","current":-3.871352,"twenty":-6.164946,"median":-4.528752,"eighty":-3.842134,"marketCap":75582291},{"date":"2024-12-27","current":-3.50613,"twenty":-6.135728,"median":-4.435255,"eighty":-3.725263,"marketCap":68451887},{"date":"2025-01-03","current":-4.012144,"twenty":-6.10651,"median":-4.399098,"eighty":-3.717959,"marketCap":84851818},{"date":"2025-01-10","current":-3.992285,"twenty":-6.033466,"median":-4.399098,"eighty":-3.747177,"marketCap":84431834},{"date":"2025-01-17","current":-4.465946,"twenty":-5.967726,"median":-4.376046,"eighty":-3.723807,"marketCap":94449170},{"date":"2025-01-24","current":-4.296782,"twenty":-5.953117,"median":-4.35308,"eighty":-3.739872,"marketCap":90871550},{"date":"2025-01-31","current":-4.262949,"twenty":-5.953117,"median":-4.346141,"eighty":-3.761786,"marketCap":90156026},{"date":"2025-02-07","current":-4.026118,"twenty":-5.938508,"median":-4.309619,"eighty":-3.767526,"marketCap":85147358},{"date":"2025-02-14","current":-4.330615,"twenty":-5.916595,"median":-4.296782,"eighty":-3.799613,"marketCap":91587074},{"date":"2025-02-21","current":-3.72014,"twenty":-5.901986,"median":-4.296782,"eighty":-3.761786,"marketCap":85862882},{"date":"2025-02-28","current":-3.689139,"twenty":-5.807029,"median":-4.262949,"eighty":-3.720436,"marketCap":85147358},{"date":"2025-03-07","current":-3.162119,"twenty":-5.639027,"median":-4.229116,"eighty":-3.689139,"marketCap":72983450},{"date":"2025-03-14","current":-2.294087,"twenty":-5.507546,"median":-4.152992,"eighty":-3.653403,"marketCap":52948777},{"date":"2025-03-21","current":-1.891071,"twenty":-5.317631,"median":-4.127617,"eighty":-3.617985,"marketCap":43646965},{"date":"2025-03-28","current":-2.030577,"twenty":-5.251891,"median":-4.059951,"eighty":-3.565808,"marketCap":46866823},{"date":"2025-04-04","current":-2.191783,"twenty":-5.220193,"median":-4.053963,"eighty":-3.506186,"marketCap":50587548},{"date":"2025-04-11","current":-1.919282,"twenty":-5.198143,"median":-4.02178,"eighty":-3.38992,"marketCap":44298092},{"date":"2025-04-17","current":-2.002676,"twenty":-5.149629,"median":-4.014793,"eighty":-3.224122,"marketCap":46222851},{"date":"2025-04-25","current":-1.987175,"twenty":-5.113107,"median":-3.992285,"eighty":-3.104751,"marketCap":45865089},{"date":"2025-05-02","current":-2.759104,"twenty":-5.076585,"median":-3.944397,"eighty":-2.759104,"marketCap":63681637},{"date":"2025-05-09","current":-2.619599,"twenty":-4.930496,"median":-3.907874,"eighty":-2.693382,"marketCap":60461779},{"date":"2025-05-16","current":-2.437632,"twenty":-4.930496,"median":-3.890787,"eighty":-2.691522,"marketCap":63331031},{"date":"2025-05-23","current":-2.506208,"twenty":-4.784407,"median":-3.875146,"eighty":-2.619599,"marketCap":65112685},{"date":"2025-05-30","current":-2.451953,"twenty":-4.784407,"median":-3.871352,"eighty":-2.502848,"marketCap":63703103},{"date":"2025-06-06","current":-2.671453,"twenty":-4.755189,"median":-3.805483,"eighty":-2.487546,"marketCap":69405829},{"date":"2025-06-13","current":-4.04849,"twenty":-4.660231,"median":-3.776135,"eighty":-2.502848,"marketCap":105182030},{"date":"2025-06-20","current":-4.268817,"twenty":-4.617062,"median":-3.83483,"eighty":-2.506208,"marketCap":110906223},{"date":"2025-06-27","current":-9.639263,"twenty":-4.842843,"median":-3.873249,"eighty":-2.506208,"marketCap":250433407},{"date":"2025-07-03","current":-14.569058,"twenty":-5.098498,"median":-3.876214,"eighty":-2.511716,"marketCap":378512206},{"date":"2025-07-11","current":-8.950744,"twenty":-5.244587,"median":-3.890787,"eighty":-2.545647,"marketCap":232545306},{"date":"2025-07-18","current":-4.40652,"twenty":-5.303022,"median":-3.909331,"eighty":-2.598329,"marketCap":114483843},{"date":"2025-07-25","current":-5.370447,"twenty":-5.303022,"median":-3.944397,"eighty":-2.622079,"marketCap":139527183},{"date":"2025-08-01","current":-7.246465,"twenty":-5.617113,"median":-3.968341,"eighty":-2.631999,"marketCap":188267172},{"date":"2025-08-08","current":-6.066045,"twenty":-5.92757,"median":-3.993409,"eighty":-2.65122,"marketCap":157599217},{"date":"2025-08-15","current":-5.071831,"twenty":-5.92757,"median":-4.017441,"eighty":-2.668242,"marketCap":134797404},{"date":"2025-08-22","current":-4.806444,"twenty":-5.916595,"median":-4.026118,"eighty":-2.679481,"marketCap":127744051},{"date":"2025-08-29","current":-6.251327,"twenty":-5.92757,"median":-4.051227,"eighty":-2.692266,"marketCap":166145638},{"date":"2025-09-05","current":-5.514142,"twenty":-5.933303,"median":-4.056957,"eighty":-2.700326,"marketCap":146552992},{"date":"2025-09-12","current":-5.938837,"twenty":-5.933303,"median":-4.063335,"eighty":-2.734303,"marketCap":157840405},{"date":"2025-09-19","current":-5.498923,"twenty":-5.933303,"median":-4.134553,"eighty":-2.759104,"marketCap":146148523},{"date":"2025-09-26","current":-5.71888,"twenty":-5.924891,"median":-4.16145,"eighty":-2.75929,"marketCap":151994464},{"date":"2025-10-03","current":-5.907415,"twenty":-5.938047,"median":-4.221426,"eighty":-2.76177,"marketCap":157005270},{"date":"2025-10-10","current":-5.750303,"twenty":-5.938047,"median":-4.262949,"eighty":-2.769272,"marketCap":152829598},{"date":"2025-10-17","current":-5.624613,"twenty":-5.934887,"median":-4.265883,"eighty":-2.785269,"marketCap":149489061},{"date":"2025-10-24","current":-5.247544,"twenty":-5.933303,"median":-4.296782,"eighty":-2.845783,"marketCap":139467448},{"date":"2025-10-31","current":-5.436079,"twenty":-5.924891,"median":-4.3032,"eighty":-2.870708,"marketCap":144478254},{"date":"2025-11-07","current":-4.524828,"twenty":-5.916595,"median":-4.309619,"eighty":-2.884898,"marketCap":120259356},{"date":"2025-11-14","current":-4.179182,"twenty":-5.914759,"median":-4.309619,"eighty":-2.896465,"marketCap":111072877},{"date":"2025-11-21","current":-3.550733,"twenty":-5.907415,"median":-4.304871,"eighty":-2.952238,"marketCap":94370189},{"date":"2025-11-28","current":-4.304871,"twenty":-5.907415,"median":-4.296782,"eighty":-3.104751,"marketCap":114413415},{"date":"2025-12-05","current":-3.487889,"twenty":-5.875992,"median":-4.296782,"eighty":-3.112056,"marketCap":92699920},{"date":"2025-12-12","current":-3.550733,"twenty":-5.86799,"median":-4.273096,"eighty":-3.162119,"marketCap":94370189},{"date":"2025-12-19","current":-3.582156,"twenty":-5.84457,"median":-4.262949,"eighty":-3.19281,"marketCap":95205323},{"date":"2025-12-26","current":-3.92117,"twenty":-5.843755,"median":-4.262949,"eighty":-3.21786,"marketCap":97093533},{"date":"2026-01-02","current":-3.424602,"twenty":-5.82283,"median":-4.235196,"eighty":-3.269261,"marketCap":84797846},{"date":"2026-01-09","current":-3.869801,"twenty":-5.792641,"median":-4.210604,"eighty":-3.333795,"marketCap":95821565},{"date":"2026-01-16","current":-3.698571,"twenty":-5.781725,"median":-4.16249,"eighty":-3.356755,"marketCap":91581673},{"date":"2026-01-23","current":-3.835555,"twenty":-5.769156,"median":-4.143012,"eighty":-3.358933,"marketCap":94973587},{"date":"2026-01-30","current":-3.921541,"twenty":-5.737734,"median":-4.109523,"eighty":-3.368971,"marketCap":97102724},{"date":"2026-02-06","current":-3.957191,"twenty":-5.706311,"median":-4.080473,"eighty":-3.382482,"marketCap":97985476},{"date":"2026-02-12","current":-4.028492,"twenty":-5.687458,"median":-4.061643,"eighty":-3.39493,"marketCap":99750980}],"updateTime":1770992752986},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTOR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611522871","title":"Citius Oncology Inc. posts Q1 net loss of USD 5.53 million, down 17 percent","url":"https://stock-news.laohu8.com/highlight/detail?id=2611522871","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611522871?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:02","pubTimestamp":1770987756,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc. reported its financial results for the quarter ended December 31, 2025. The company recorded a net loss of USD 5.53 million for the period, compared to a net loss of USD 6.66 million in the same quarter of the previous year, reflecting a decrease of 17 percent. Revenue commenced in December 2025 following the commercial launch of LYMPHIR , an approved oncology immunotherapy for the treatment of cutaneous T-cell lymphoma, contributing to a gross profit of USD 3.15 million for the quarter. As of December 31, 2025, Citius Oncology had an accumulated deficit of USD 69.57 million. The company noted that it has historically relied on funding from Citius Pharma and recently completed equity offerings, projecting that it and Citius Pharma collectively will have sufficient funds to continue operations through May 2026. Citius Oncology has retained Jefferies LLC as its exclusive financial advisor to evaluate strategic alternatives to maximize shareholder value. The company p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL2zrf30:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR","BK4127","CTXR","BK4007","BK4559","JEF"],"gpt_icon":0},{"id":"2611524271","title":"Citius Pharma Q1 stock-based compensation expense rises to USD 3.56 million, up 97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611524271","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611524271?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:01","pubTimestamp":1770987719,"startTime":"0","endTime":"0","summary":"Citius Pharmaceuticals Inc. reported its earnings for the three months ended December 31, 2025. The company posted interest income of USD 0.05 million for the quarter. Interest expense totaled USD 0.16 million for the same period, primarily attributed to the March 28, 2025 letter agreement with Eisai and the note payable, including the fair value of the warrant issued to the lender. Stock-based compensation expense for the quarter increased by USD 1.76 million, mainly due to Citius Oncology restricted stock awards granted in September 2025. During the period, Citius Pharmaceuticals continued its focus on the development and commercialization of first-in-class critical care products. The company highlighted its obligations related to Citius Oncology, including milestone payments and tiered royalties to Dr. Reddy’s, as well as provisions for sublicensing revenue sharing. The company also noted the dissolution of Citius Pharmaceuticals, LLC in December 2023 and ongoing investments from pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL4T3W5G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4007","BK4139","CTXR"],"gpt_icon":0},{"id":"2610301579","title":"Citius Oncology Signs Exclusive Distribution Agreement With Uniphar for LYMPHIR in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2610301579","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610301579?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:14","pubTimestamp":1770815656,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc. announced it has entered into an exclusive distribution agreement with Uniphar, an international healthcare services company, to support access to LYMPHIR  outside the United States. Under the agreement, Uniphar will act as the exclusive distribution partner for LYMPHIR in designated territories across Western and Eastern Europe through country-specific managed access programs, subject to local regulations. This marks the third international distribution partnership for Citius Oncology as part of its global expansion strategy. LYMPHIR is not approved for commercial use outside the United States and will be provided in these territories only through managed access programs, which do not constitute marketing authorization or a commercial launch.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLKN0ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","CTOR","BK4007","BK4139"],"gpt_icon":0},{"id":"2610004937","title":"Citius Oncology Expands International Distribution of Lymphir™ to European Union Through Exclusive Agreement With Uniphar","url":"https://stock-news.laohu8.com/highlight/detail?id=2610004937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610004937?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:00","pubTimestamp":1770814805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA4QGQJT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTXR","BK4139","BK4007","CTOR"],"gpt_icon":0},{"id":"2607516260","title":"Citius Oncology Inc. Files Information Statement Detailing Authorized Corporate Actions","url":"https://stock-news.laohu8.com/highlight/detail?id=2607516260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607516260?lang=en_us&edition=fundamental","pubTime":"2026-01-30 05:31","pubTimestamp":1769722261,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc. has announced that its shareholders authorized certain corporate actions by written consent as of January 20, 2026. The company’s Board of Directors has informed stockholders of these approved actions. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL3pFqY2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4007","CTOR","BK4139"],"gpt_icon":0},{"id":"2605214191","title":"Citius Oncology Inc. Files Draft Information Statement Outlining Authorized Corporate Actions","url":"https://stock-news.laohu8.com/highlight/detail?id=2605214191","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605214191?lang=en_us&edition=fundamental","pubTime":"2026-01-21 05:31","pubTimestamp":1768944706,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc. has announced that its shareholders have authorized certain corporate actions as of January 20, 2026. The company provided an information statement to update shareholders regarding the approved actions. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL1qsW0L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR","BK4007","CTXR"],"gpt_icon":0},{"id":"2593443058","title":"Citius Oncology Q4 EPS $(0.06), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2593443058","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593443058?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:39","pubTimestamp":1766525991,"startTime":"0","endTime":"0","summary":"Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 57.14 percent increase over losses of $(0.14) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/12/49574953/citius-oncology-q4-eps-0-06-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Citius Oncology Q4 EPS $(0.06), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2593443641","title":"Citius Oncology posts FY cash balance of USD 3.9 million and accumulated deficit of USD 64.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2593443641","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593443641?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:22","pubTimestamp":1766524929,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc. reported its full year  financial results for the period ending September 30, 2025. The company posted an accumulated deficit of USD 64.0 million and had no revenue for the period. As of September 30, 2025, Citius Oncology Inc. reported cash holdings of USD 3.9 million and a negative working capital of approximately USD 21.9 million. During the fiscal year, the company raised net proceeds of approximately USD 15 million from equity offerings. Citius Pharma, the parent company, also raised net proceeds of approximately USD 32 million from equity offerings and USD 1 million from a note payable.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL1Jb4W6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4007","CTXR","BK4139"],"gpt_icon":0},{"id":"2590565455","title":"Citius Oncology Announces Warrant and Share Issuance in $18 Million Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590565455","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590565455?lang=en_us&edition=fundamental","pubTime":"2025-12-11 06:29","pubTimestamp":1765405785,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc. has announced agreements involving the issuance of warrants and share rights as part of an $18 million concurrent registered direct offering and private placement. The company will issue unregistered warrants to purchase up to 1,284,404 shares of common stock at $1.09 per share in the registered direct offering, and additional warrants to purchase up to 15,229,358 shares of common stock at $1.09 per share in a private placement. The exercise of these warrants is contingent on stockholder approval and they will expire five years from the date of such approval. Additionally, Citius Oncology will amend previously issued warrants, reducing their exercise price to $1.09 per share, effective upon closing of the offerings. Proceeds will support the commercial launch of LYMPHIR, a cancer immunotherapy for cutaneous T-cell lymphoma.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL4PPKCz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CTOR","CTXR"],"gpt_icon":0},{"id":"2590553628","title":"Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2590553628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590553628?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:30","pubTimestamp":1765402200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA8QJX98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTOR","BK4139"],"gpt_icon":0},{"id":"2590341455","title":"Citius Oncology Sells Shares and Warrants in $18 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341455","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590341455?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:45","pubTimestamp":1765287915,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc. has announced a private placement involving the sale of shares of its common stock, pre-funded warrants, and warrants to a single healthcare-focused investor. These securities, along with unregistered warrants to purchase additional shares, are being offered in a private placement under Section 4 of the Securities Act and/or Regulation D. The shares and warrants sold in the private placement have not been registered under the Securities Act or state securities laws and can only be resold under an effective registration statement or an applicable exemption. The company has agreed to file a registration statement with the SEC to cover the resale of these securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL684HsL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4139","BK4007","CTOR"],"gpt_icon":0},{"id":"2590842341","title":"Citius Oncology Inc - Proceeds Support Launch of Lymphir for Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2590842341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590842341?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:30","pubTimestamp":1765287003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUAJB85X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CTOR","CTXR","BK4007"],"gpt_icon":0},{"id":"2590341358","title":"Citius Oncology Inc - to Purchase 1,284,404 Shares of Common Stock at $1.09 per Share in Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590341358?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:30","pubTimestamp":1765287003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUAJB85X:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTXR","CTOR","BK4007","BK4139"],"gpt_icon":0},{"id":"2590341345","title":"Press Release: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341345","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590341345?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:30","pubTimestamp":1765287000,"startTime":"0","endTime":"0","summary":"Proceeds strengthen cash position and support commercial launch of LYMPHIR, a novel cancer immunotherapy for cutaneous T-cell lymphoma . Concurrently with the registered direct offering, in a private placement priced at-the-market under Nasdaq rules, the Company entered into a definitive agreement with the investor for the purchase and sale of 15,229,358 shares of common stock  and warrants to purchase up to 15,229,358 shares of the Company's common stock at a purchase price of $1.09 per share and accompanying warrant. The warrants to be issued in the private placement have an exercise price of $1.09 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants and will expire five years from the date of stockholder approval.The shares of common stock  being offered in the registered direct are being offered by the Company pursuant to a \"shelf\" registration statement on Form S-3  that w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4585","BK4588","BK4604","BK4099","NQmain","BK4139","03160","CTOR","BK4555"],"gpt_icon":0},{"id":"2588887889","title":"BRIEF-Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2588887889","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588887889?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:44","pubTimestamp":1764855868,"startTime":"0","endTime":"0","summary":"BRIEF-Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries Dec 4 (Reuters) - Citius Oncology Inc CTOR.O:CITIUS ONCOLOGY EXPANDS LYMPHIR DISTRIBUTION TO TURKEY AND MIDDLE EA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA8B8B6C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4139","BK4007","CTXR"],"gpt_icon":0},{"id":"2588882226","title":"Citius Oncology Expands Lymphir™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement With Er-Kim","url":"https://stock-news.laohu8.com/highlight/detail?id=2588882226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588882226?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:37","pubTimestamp":1764855420,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA8B8B6C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","CTXR","CTOR"],"gpt_icon":0},{"id":"2588970586","title":"Citius Pharmaceuticals Highlights Oncology Pipeline and LYMPHIR Launch in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2588970586","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588970586?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:42","pubTimestamp":1764625336,"startTime":"0","endTime":"0","summary":"Citius Pharmaceuticals Inc. has provided an update on its advanced development programs in the biopharmaceutical sector. The company highlighted the launch of LYMPHIR  in December 2025 for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma  after at least one prior systemic therapy. LYMPHIR is the first marketed product by Citius Oncology, Inc. , which became a stand-alone public company in August 2024 and remains a majority-owned subsidiary of Citius Pharmaceuticals. Other programs featured include Mino-Lok, a treatment designed to salvage infected catheters causing central line-associated bloodstream infections , which has completed a Phase 3 trial with positive topline data, and Halo-Lido, a prescription therapy in development for hemorrhoids, which has completed a Phase 2b trial. The presentation notes that Citius Oncology has established a shared management services agreement with Citius Pharmaceuticals to support operational efficien","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL2Ff77C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4007","CTOR","BK4139"],"gpt_icon":0},{"id":"2588570777","title":"BRIEF-Citius Oncology Announces U.S. Commercial Launch Of Lymphir For Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2588570777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588570777?lang=en_us&edition=fundamental","pubTime":"2025-12-02 02:31","pubTimestamp":1764613866,"startTime":"0","endTime":"0","summary":"BRIEF-Citius Oncology Announces U.S. Commercial Launch Of Lymphir For Cutaneous T-Cell LymphomaDec 1 (Reuters) - Citius Oncology Inc CTOR.O:CITIUS ONCOLOGY ANNOUNCES U.S. COMMERCIAL LAUNCH OF LYMPHIR,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA78MRJT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2588772937","title":"Citius Oncology Shares Rise After Cancer Treatment Launches","url":"https://stock-news.laohu8.com/highlight/detail?id=2588772937","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588772937?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:43","pubTimestamp":1764610980,"startTime":"0","endTime":"0","summary":"Citius Oncology shares climbed after the company commercially launched its treatment Lymphir for patients with a rare type of cancer that affects the skin.The stock rose 14.5% to $1.57 on Monday. Shares have gained 37% this year.Lymphir, which is approved by the Food and Drug Administration to treat adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma, will now be available throughout the U.S., the Cranford, N.J., company said Monday.A phase 3 trial demonstrated an objective response rate of 36%, with 84% of evaluable patients experiencing a reduction in skin tumor burden, Citius said. The median time to response was 1.4 months.Lymphir may offer rapid skin relief to patients experiencing itching, which is common with lymphoma, the company said.Outside the U.S., Citius holds exclusive rights to develop and commercialize Lymphir in all global markets except India, Japan and certain parts of Asia.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Citius Oncology Shares Rise After Cancer Treatment Launches","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2588120774","title":"Citius Oncology Announces U.S. Commercial Launch of Lymphir™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (Ctcl)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588120774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588120774?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:00","pubTimestamp":1764608401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA78MRJT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","CTOR","CTXR"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}